NCT06681363 Creation of a Biocollection of Patients With Acute Myeloid Leukemia (AML) or Lymphoid Leukemia (ALL) or High-risk Myelodysplastic Syndrome (MDS) Monitored at the Nantes University Hospital
| NCT ID | NCT06681363 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Nantes University Hospital |
| Condition | Acute Myeloid Leucemia |
| Study Type | OBSERVATIONAL |
| Enrollment | 1,000 participants |
| Start Date | 2026-05-21 |
| Primary Completion | 2036-05-21 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 1,000 participants in total. It began in 2026-05-21 with a primary completion date of 2036-05-21.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The aim of the LANA bio-collection is to collect samples from patients with Acute Myeloid Leukemia (AML), Acute Lymphocytic Leukemia (ALL) or or high-risk myelodysplastic syndrome (MDS) to facilitate access to the leukemic or myelodysplastic cells for the research teams of the National Institute of Health and Medical Research (INSERM). To do this, an additional blood or bone marrow sample to those planned in the context of patient care will be collected after signing consent. These samples will then be sent directly to the INSERM teams for immediate analysis with the aim to conduct research aimed at a better understanding of AML, ALL or MDS and improving treatments
Eligibility Criteria
Inclusion Criteria: * Patient of legal age affected by AML, ALL or MDS regardless of the time of treatment * Patient who has signed the consent form. * Patient affiliated with a social security system. Exclusion Criteria: * Minor patients. * Adults under guardianship. * Protected persons
Contact & Investigator
Pierre Peterlin
PRINCIPAL INVESTIGATOR
Nantes University Hospital
Frequently Asked Questions
Who can join the NCT06681363 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Acute Myeloid Leucemia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06681363 currently recruiting?
Yes, NCT06681363 is actively recruiting participants. Contact the research team at Pierre.PETERLIN@chu-nantes.fr for enrollment information.
Where is the NCT06681363 trial being conducted?
This trial is being conducted at Nantes, France.
Who is sponsoring the NCT06681363 clinical trial?
NCT06681363 is sponsored by Nantes University Hospital. The principal investigator is Pierre Peterlin at Nantes University Hospital. The trial plans to enroll 1,000 participants.